PRTA News and Press, Prothena Corporation plc From 09/21/23

2023-09-21 13:39:18 ET Summary Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX012, is an amyloid clearing drug that is currently in Phase 1 clinical trials. Prothena also has...

2023-09-14 13:02:36 ET More on Alzheimer's drug developers Cassava Sciences: Insiders Purchasing Stock, Is The Market Still Buying Simufilam? Prothena: Dunn Appointment And Bristol Opt-In Boost Validation Anavex Life Sciences: Multiple CNS Shots On Goal Awaiting Conv...

2023-09-07 11:04:48 ET More on Lilly, Novo, etc. Novo Nordisk: Super Focused Pharma Company For The Long Run Novo Nordisk: Strong Fundamentals Meet Technical Uptrends Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad? Se...

2023-08-03 17:33:59 ET Prothena press release ( NASDAQ: PRTA ): Q2 GAAP EPS of -$1.03 misses by $0.06 . Revenue of $4M (+207.7% Y/Y) misses by $0.52M . Revised year-end cash guidance to be approximately $600 million in cash, cash equivalents and restricted cash...

Net cash used in operating and investing activities was $45.7 million in the second quarter and $93.2 million for the first six months of 2023; quarter-end cash and restricted cash position was $661.3 million Revised year-end cash guidance to be approximately $600 million in cash, cash equiva...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2023 financial results on Thursday, A...

2023-07-27 07:23:03 ET Summary Prothena, a late-stage biotech firm, has appointed former FDA official Dr. Billy Dunn to its board and is developing therapies for neurodegenerative and rare peripheral amyloid diseases with strategic partners. The company's key candidate, Birtamimab...

Data from PRX012, PRX005 and PRX123 programs showcase promise of Prothena’s pipeline and commitment to transform the care of patients with Alzheimer's disease Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigati...

2023-07-13 08:03:58 ET Summary Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique binding profile. Results of the ...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced participation in the Alzheimer’s Association International Conference ® 2023 (AAIC ...